Please join PetDx at the American College of Veterinary Pathologists Annual Meeting in Boston, Massachusetts.

Exhibit Hall Booth #305

• November 12, 2022 – 7:00 pm – 9:00 pm EST
• November 13, 2022 – 9:30 am – 4:00 pm EST
• November 14, 2022 – 9:30 am – 4:00 pm EST
• November 15, 2022 – 9:30 am – 1:30 pm EST

Presentation

• Title: D26: Clinical Laboratory Experience With a Next-generation Sequencing-based Liquid Biopsy Test for Cancer Detection in Dogs
• Date: November 13, 2022
• Presenter: Dr. Andi Flory, DVM, DACVIM (Oncology)
• Authors: Andi Flory, Katherine Lytle, Emily Sandford, Todd Cohen, Allison O’Kell, Angela McCleary-Wheeler, Kristina Kruglyak, John Tynan, Susan Hicks, Daniel Grosu, Jill Rafalko, Jason Chibuk, Ilya Chorny, Dana Tsui
• Background: Next-generation sequencing-based liquid biopsy testing for cancer detection in dogs became clinically available in 2021 and has since been used in a variety of clinical settings.
• Objective: This study reviews ordering patterns and outcome data from samples submitted for commercial testing at one clinical laboratory.
• Methods: Clinical data were analyzed from 1,500 consecutive blood samples submitted for liquid biopsy testing.
• Results: Over 60% of cases were referred for liquid biopsy as a screening test for dogs with no current suspicion of cancer, another ~25% as an aid-in-diagnosis for dogs suspected of having cancer, and ~10% of cases for “other” indications, including post-diagnosis uses such as minimal residual disease detection and recurrence monitoring. The positivity rate was <10% for the screening population and >25% for the aid-in-diagnosis population. Indeterminate results (in which genomic alterations were detected but their significance was uncertain and a complimentary redraw was advised) were uncommon, representing <3% of cases; when a redraw was submitted, the vast majority of cases received a clear positive/negative report on the second test. Outcome data were available for a subset of patients and the observed positive predictive value compared favorably with that of liquid biopsy tests used in human medicine.
• Conclusions: Once a test is clinically validated and available commercially, it is important for the laboratory to periodically report utilization and performance metrics regarding the test. This observational study provides data demonstrating that most dogs who receive a positive liquid biopsy result are diagnosed with cancer following a confirmatory cancer evaluation.

Register for ACVP 2022